Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug sotatercept tested to slow PAH progression

NCT ID NCT04811092

Disease control Sponsor: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 3 trial tested the drug sotatercept in 321 people newly diagnosed with intermediate- or high-risk pulmonary arterial hypertension (PAH). Participants received either sotatercept or a placebo added to their usual PAH therapy. The goal was to see if sotatercept could delay clinical worsening, such as hospitalization or death. However, the study was terminated early, so the full results are not available.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
sotatercept (a drug given by injection under the skin)
What this could lead to
If it works, this could provide a new treatment option to delay worsening of PAH in newly diagnosed patients.
What could go wrong
The trial was terminated early, so results are limited. It is unclear if sotatercept is effective or safe in this specific group.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

321 people

The number who actually took part.

Started

Mar 2022

Finished

Apr 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Inclusion criteria include but are not limited to: * Documented diagnostic right heart catheterization (RHC) within 12 months of screening documenting a minimum pulmonary vascular resistance (PVR) of ≥ 4 Wood units and pulmonary capillary wedge pressure (PCWP) or left ventricular end-diastolic pressure (LVEDP) of ≤ 15 mmHg, with the diagnosis of WHO PAH Group 1 in any of the following subtypes: * Idiopathic PAH * Heritable PAH * Drug/toxin-induced PAH * PAH associated with connective tissue disease * PAH associated with simple, congenital systemic to pulmonary shunts at least 1 year following repair * Symptomatic PAH classified as World Health Organization (WHO) Functional Class (FC) II or III * Either Registry to Evaluate Early and Long-term PAH Disease Management (REVEAL) Lite 2 Risk Score ≥ 6 or Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA) 2.0 risk score ≥2 (intermediate to-low-risk or above) * Diagnosis of PAH within 12 months of screening and on stable doses of a double or triple combination of background PAH therapies and diuretics (if any) for at least 90 days prior to screening * Six-minute walk distance ≥ 150 m repeated twice at screening at least 4 hours apart, but no longer than 1 week apart, and both values are within 15% of each other (calculated from the highest value) * Females of childbearing potential must meet the following criteria: * Have 2 negative urine or serum pregnancy tests as verified by the investigator prior to starting study drug administration; she must agree to ongoing urine or serum pregnancy testing during the course of the study and until 8 weeks after the last dose of the study drug * If sexually active with a male partner, have used highly effective contraception without interruption, for at least 28 days prior to starting the investigational product AND agreed to use the same highly effective contraception in combination with a barrier method during the study (including dose interruptions) and for 16 weeks (112 days) after discontinuation of study treatment * Refrain from breastfeeding a child or donating blood, eggs, or ovum for the duration of the study and for at least 16 weeks (112 days) after the last dose of study treatment * Male participants must meet the following criteria: * Agree to use a condom, defined as a male latex condom or nonlatex condom NOT made out of natural (animal) membrane (e.g., polyurethane), during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions, and for at least 16 weeks (112 days) following investigational product discontinuation, even if he has undergone a successful vasectomy * Refrain from donating blood or sperm for the duration of the study and for 16 weeks (112 days) after the last dose of study treatment Exclusion Criteria: Exclusion Criteria include but are not limited to: * Diagnosis of pulmonary hypertension (PH) WHO Groups 2, 3, 4, or 5 * Diagnosis of the following PAH Group 1 subtypes: human immunodeficiency virus (HIV)-associated PAH and PAH associated with portal hypertension, schistosomiasis-associated PAH, pulmonary veno occlusive disease, and pulmonary capillary hemangiomatosis * Hemoglobin at screening above gender-specific upper limit of normal (ULN), per local laboratory test * Uncontrolled systemic hypertension as evidenced by sitting systolic blood pressure (BP) \> 180 mmHg or sitting diastolic BP \> 110 mmHg during the Screening Visit after a period of rest * Baseline systolic BP \< 90 mmHg at screening * Pregnant or breastfeeding women * Any of the following clinical laboratory values at the Screening Visit: * Estimated glomerular filtration rate \< 30 mL/min/1.73 m\^2 (as defined by The Modification of Diet in Renal Disease \[MDRD\] equation) * Serum alanine aminotransferase, aspartate aminotransferase, and total bilirubin levels \> 3 × ULN * Platelet count \< 50,000/mm\^3 (\< 50.0 × 10\^9 /L) * Currently enrolled in or have completed any other investigational product study within 30 days for small molecule drugs or within 5 half-lives for investigational biologics prior to the date of documented informed consent * Known allergic reaction to sotatercept (ACE-011), its excipients, or luspatercept * History of pneumonectomy * Pulmonary function test values of forced vital capacity \< 60% predicted within 1 year prior to the Screening Visit * Stopped receiving any PH chronic general supportive therapy (e.g., diuretics, oxygen, anticoagulants, and digoxin) within 60 days prior to the Screening Visit * Initiation of an exercise program for cardiopulmonary rehabilitation within 90 days prior to the Screening Visit or planned initiation during the study (participants who are stable in the maintenance phase of a program and who will continue for the duration of the study are eligible) * Untreated more than mild obstructive sleep apnea * History of known pericardial constriction * History of restrictive or congestive cardiomyopathy * History of atrial septostomy within 180 days prior to the Screening Visit * Electrocardiogram with Fridericia's corrected QT interval \> 500 ms during the Screening Period * Personal or family history of long QT syndrome or sudden cardiac death * Left ventricular ejection fraction \< 50% on historical echocardiogram (ECHO) within 1 year prior to the Screening Visit * Any current or prior history of symptomatic coronary disease (prior myocardial infarction, percutaneous coronary intervention, coronary artery bypass graft surgery, or cardiac anginal chest pain) in the past 6 months prior to the Screening Visit * Cerebrovascular accident within 3 months prior to the Screening Visit * Acutely decompensated heart failure within 30 days prior to the Screening Visit, as per investigator assessment * Significant (≥ 2+ regurgitation) mitral regurgitation or aortic regurgitation valvular disease * Received intravenous inotropes (e.g., dobutamine, dopamine, norepinephrine, and vasopressin) within 30 days prior to the Screening Visit * Has an active malignancy with the exception of fully excised or treated basal cell carcinoma, cervical carcinoma in-situ, or prostate cancer that is not currently or expected, during the study, to be treated with radiation therapy, chemotherapy, and/or surgical intervention, or hormonal treatment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pulmonary arterial hypertension are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hypertensive disorder pulmonary arterial hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pulmonary arterial hypertension

Contacts and locations

Locations

  • AHEPA University General Hospital of Thessaloniki ( Site 3601)

    Thessaloniki, 546 36, Greece

  • Aarhus Universitetshospital, Skejby ( Site 3801)

    Aarhus, Central Jutland, 8200, Denmark

  • AdventHealth Medical Group Advanced Lung Disease ( Site 1058)

    Orlando, Florida, 32804, United States

  • Arizona Pulmonary Specialists ( Site 1010)

    Scottsdale, Arizona, 85258, United States

  • Assuta Ashdod Medical Center ( Site 1710)

    Ashdod, 7747629, Israel

  • Attikon University General Hospital of Athens ( Site 3604)

    Haidari, Attica, 124 62, Greece

  • Azienda Ospedaliera R. N. V. Monaldi ( Site 2407)

    Naples, 80131, Italy

  • Azienda Ospedaliera San Gerardo di Monza ( Site 2406)

    Monza, Monza E Brianza, 20900, Italy

  • Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI) ( Site 2405)

    Trieste, Friuli Venezia Giulia, 34149, Italy

  • Boston Medical Center ( Site 1012)

    Boston, Massachusetts, 02118, United States

  • C.H.U. de Nancy. Hopital de Brabois Adultes ( Site 1308)

    Vandœuvre-lès-Nancy, Meurthe-et-Moselle, 54500, France

  • C.H.U. de Tours - Hopital Bretonneau ( Site 1310)

    Tours, Indre-et-Loire, 37000, France

  • CHU - Hopital de Bicetre ( Site 1304)

    Le Kremlin-Bicêtre, Val-de-Marne, 94270, France

  • CHU Angers ( Site 1313)

    Angers, Maine-et-Loire, 49933, France

  • CHU Caen Normandie ( Site 1325)

    Caen, Calvados, 14033, France

  • CHU de Besancon ( Site 1303)

    Besançon, Doubs, 25000, France

  • CHU de Poitiers ( Site 1316)

    Poitiers, Vienne, 86000, France

  • CHU de Toulouse - Hopital Larrey ( Site 1315)

    Toulouse, Haute-Garonne, 31059, France

  • Cardiologia Palermo ( Site 1911)

    Ciudad Autonoma de Buenos Aires, Buenos Aires, C1425BNG, Argentina

  • Centre Hospitalier Universitaire de Saint-Etienne ( Site 1302)

    Saint-Priest-en-Jarez, Pays de la Loire Region, 42270, France

  • Centro Cardiovascular Colombiano Clínica Santa María Clínica Cardio VID ( Site 3402)

    Medellín, Antioquia, 50034, Colombia

  • Centro Hospitalar E Universitário De Coimbra ( Site 3502)

    Coimbra, 3000-075, Portugal

  • Centro Medico Dra De Salvo ( Site 1904)

    Ciudad Autonoma de Buenos Aires, Buenos Aires, C1426ABP, Argentina

  • Centro Medico Imbanaco de Cali S.A ( Site 3404)

    Cali, Valle del Cauca Department, 760042, Colombia

  • China Medical University Hospital ( Site 3701)

    Taichung, 40447, Taiwan

  • Chonnam National University Hospital ( Site 3105)

    Gwangju, Kyonggi-do, 61469, South Korea

  • Clinical Center Kragujevac ( Site 2905)

    Kragujevac, Sumadijski Okrug, 34000, Serbia

  • Clinical Center of Serbia ( Site 2901)

    Belgrade, 11000, Serbia

  • DRK Kliniken Berlin Westend ( Site 1507)

    Berlin, 14050, Germany

  • Erasmus MC ( Site 2604)

    Rotterdam, South Holland, 3015 GD, Netherlands

  • Evangelismos General Hospital of Athens ( Site 3605)

    Athens, Attica, 106 76, Greece

  • Fiona Stanley Hospital ( Site 1103)

    Murdoch, Western Australia, 6150, Australia

  • Freeman Hospital ( Site 1205)

    Newcastle upon Tyne, NE7 7DN, United Kingdom

  • Fundacion Neumologica Colombiana ( Site 3403)

    Bogota, Cundinamarca, 110131, Colombia

  • Fundacion Valle Del Lili ( Site 3401)

    Cali, Valle del Cauca Department, 760032, Colombia

  • Gachon University Gil Medical Center ( Site 3103)

    Namdong-Gu, Incheon, 21565, South Korea

  • Golden Jubilee National Hospital ( Site 1204)

    Glasgow, Glasgow City, G81 4DY, United Kingdom

  • Hadassah Medical Center ( Site 1711)

    Jerusalem, 9112001, Israel

  • Hjart-lungmedicin och klinisk fysiologi ( Site 3204)

    Uppsala, Uppsala County, 751 85, Sweden

  • Hopital Cavale Blanche ( Site 1314)

    Brest, Brittany Region, 29200, France

  • Hopital Erasme ( Site 1402)

    Anderlecht, Bruxelles-Capitale, Region de, 1070, Belgium

  • Hopital Haut Leveque ( Site 1312)

    Bordeaux, Gironde, 33604, France

  • Hopital Louis Pasteur ( Site 1311)

    Nice, Alpes-Maritimes, 06001, France

  • Hopital Louis Pradel ( Site 1317)

    Lyon, Auvergne, 69003, France

  • Hopital Nord Laennec ( Site 1309)

    Nantes, Loire-Atlantique, 44000, France

  • Hopitaux Universitaires de Strasbourg ( Site 1307)

    Strasbourg, Bas-Rhin, 67000, France

  • Hospital Garcia de Orta ( Site 3501)

    Almada, Setúbal District, 2801-951, Portugal

  • Hospital Madre Teresa ( Site 1804)

    Belo Horizonte, Minas Gerais, 30430-142, Brazil

  • Hospital Provincial Dr. Jose M. Cullen ( Site 1902)

    Santa Fe, S3000EOZ, Argentina

  • Hospital Provincial del Centenario ( Site 1912)

    Rosario, Santa Fe Province, 2002, Argentina

  • Hospital Pulido Valente ( Site 3503)

    Lisbon, 1769-001, Portugal

  • Hospital Sao Paulo ( Site 1806)

    São Paulo, São Paulo, 04038-031, Brazil

  • Hospital Universitari Vall de Hebron ( Site 1605)

    Barcelona, 08035, Spain

  • Hospital Universitario 12 de Octubre ( Site 1603)

    Madrid, 28041, Spain

  • Hospital Universitario Austral ( Site 1901)

    Pilar, Buenos Aires, B1629ODT, Argentina

  • Hospital Universitario La Paz ( Site 1610)

    Madrid, 28046, Spain

  • Hospital Universitario Marques de Valdecilla ( Site 1601)

    Santander, Cantabria, 39008, Spain

  • Hospital Universitario Puerta de Hierro (Majadahonda) ( Site 1604)

    Majadahonda, Madrid, 28222, Spain

  • Hospital Universitario de Salamanca - Complejo Asistencial Universitario de Salamanca ( Site 1608)

    Salamanca, 37007, Spain

  • Hospital Universitario de Son Espases ( Site 1611)

    Palma de Mallorca, Balearic Islands, 07120, Spain

  • Hospital Virgen de la Salud ( Site 1607)

    Toledo, 45004, Spain

  • Imperial College Healthcare NHS Trust ( Site 1203)

    London, London, City of, W12 OHS, United Kingdom

  • Institut Klinicke a Experimentalni Mediciny ( Site 2202)

    Prague, Praha 4, 140 21, Czechia

  • Institute for pulmonary diseases of Vojvodina ( Site 2906)

    Kamenitz, Juznobacki Okrug, 21204, Serbia

  • Instituto Cardiovascular de Rosario ( Site 1906)

    Rosario, Santa Fe Province, S2000DSR, Argentina

  • Instituto De Enfermedades Respiratorias E Investigacion Medica ( Site 1910)

    Villa Vatteone, Buenos Aires, B1853AIK, Argentina

  • Instituto Medico Rio Cuarto ( Site 1907)

    Río Cuarto, Córdoba Province, X5800AEV, Argentina

  • Instituto Médico DAMIC ( Site 1909)

    Córdoba, Córdoba Province, 5003DCE, Argentina

  • Instituto de Investigaciones Clinicas Quilmes ( Site 1903)

    Quilmes, Buenos Aires, 1878, Argentina

  • Instituto do Coracao - HCFMUSP ( Site 1803)

    São Paulo, 05403-000, Brazil

  • Instytut Gruzlicy i Chorob Pluc w Warszawie ( Site 2802)

    Warsaw, Masovian Voivodeship, 01-138, Poland

  • Irmandade da Santa Casa de Misericordia de Porto Alegre ( Site 1805)

    Porto Alegre, Rio Grande do Sul, 90020-090, Brazil

  • John Hunter Hospital ( Site 1101)

    Newcastle, New South Wales, 2308, Australia

  • Johns Hopkins Hospital ( Site 1036)

    Baltimore, Maryland, 21287-0005, United States

  • Kaohsiung Veterans General Hospital ( Site 3702)

    Kaohsiung City, 81362, Taiwan

  • Klinicki Bolnicki Centar Zagreb ( Site 3902)

    Zagreb, Zagreb County, 10000, Croatia

  • Krakowski Szpital Specjalistyczny im. Jana Pawla II ( Site 2801)

    Krakow, Lesser Poland Voivodeship, 31-202, Poland

  • Krankenhaus Neuwittelsbach ( Site 1510)

    Munich, Bavaria, 80639, Germany

  • La Sapienza-Università di Roma-Policlinico Umberto I ( Site 2402)

    Roma, 161, Italy

  • Lady Davis Carmel Medical Center ( Site 1705)

    Haifa, 3436212, Israel

  • Maastricht University Medical Center ( Site 2603)

    Maastricht, Limburg, 6229 HX, Netherlands

  • McMaster University - HSC ( Site 2105)

    Hamilton, Ontario, L8N 4A6, Canada

  • Medical University of South Carolina ( Site 1003)

    Charleston, South Carolina, 29425-8900, United States

  • Medizinische Hochschule Hannover ( Site 1505)

    Hanover, Lower Saxony, 30625, Germany

  • Medizinische Universitat Innsbruck ( Site 2004)

    Innsbruck, Tyrol, 6020, Austria

  • Medizinische Universitat Wien ( Site 2001)

    Vienna, State of Vienna, 1090, Austria

  • Medizinische Universität Graz ( Site 2003)

    Graz, Styria, 8036, Austria

  • NYU Langone Health ( Site 1052)

    New York, New York, 10016-9196, United States

  • National Cheng Kung University Hospital ( Site 3703)

    Tainan, 704, Taiwan

  • Nazih Zuhdi Transplantation Institute ( Site 1084)

    Oklahoma City, Oklahoma, 73112-4421, United States

  • Norrlands Universitetssjukhus ( Site 3205)

    Umeå, Västerbotten County, 90185, Sweden

  • Onassis Cardiac Surgery Center ( Site 3602)

    Athens, Attica, 176 74, Greece

  • Ordensklinikum Linz GmbH Elisabethinen ( Site 2002)

    Linz, Upper Austria, 4020, Austria

  • Oregon Health & Science University ( Site 1054)

    Portland, Oregon, 97239, United States

  • Ospedale S. Giuseppe Multimedica ( Site 2403)

    Milan, Lombardy, 20123, Italy

  • Papworth Hospital NHS Foundation Trust ( Site 1208)

    Cambrigge, Cambridgeshire, CB23 0AY, United Kingdom

  • Prince Charles Hospital ( Site 1104)

    Chermside, Queensland, 4032, Australia

  • Princess Alexandra Hospital ( Site 1108)

    Woolloongabba, Queensland, 4102, Australia

  • Radboud University Nijmegen Medical Centre ( Site 2605)

    Nijmegen, Gelderland, 6500 HB, Netherlands

  • Rigshospitalet ( Site 3802)

    København Ø, Capital Region, 2100, Denmark

  • Royal Adelaide Hospital ( Site 1109)

    Adelaide, South Australia, 5000, Australia

  • Royal Brompton Hospital ( Site 1206)

    London, London, City of, SW3 6HP, United Kingdom

  • Royal Free London NHS Foundation Trust ( Site 1202)

    London, London, City of, NW3 2QG, United Kingdom

  • Royal Hobart Hospital ( Site 1107)

    Hobart, Tasmania, 7000, Australia

  • Royal Prince Alfred Hospital ( Site 1106)

    Camperdown, New South Wales, 2050, Australia

  • Samsung Medical Center ( Site 3106)

    Seuol, Seoul, 06351, South Korea

  • Sanatorio Allende ( Site 1908)

    Córdoba, X5021FPQ, Argentina

  • Sanatorio Parque ( Site 1905)

    Rosario, Santa Fe Province, S2000DSV, Argentina

  • Santa Barbara Pulmonary Associates ( Site 1060)

    Santa Barbara, California, 93105-5316, United States

  • Seoul National University Hospital ( Site 3102)

    Seoul, 03080, South Korea

  • Severance Hospital Yonsei University Health System - PPDS ( Site 3101)

    Seoul, 03722, South Korea

  • Sheba Medical Center ( Site 1701)

    Tel Litwinsky, 52621, Israel

  • Sheffield Teaching Hospital NHS Foundation Trust ( Site 1207)

    Sheffield, Derbyshire, S10 2JF, United Kingdom

  • Sir Mortimer B Davis Jewish General Hospital ( Site 2103)

    Montreal, Quebec, H3T 1E2, Canada

  • Skanes Universitetssjukhus Lund ( Site 3203)

    Lund, Skåne County, 22185, Sweden

  • St Boniface General Hospital ( Site 2106)

    Winnepeg, Manitoba, R2H 2A6, Canada

  • The Carl and Edyth Lindner Center for Research and Education at the Christ Hospital ( Site 1001)

    Cincinnati, Ohio, 45219, United States

  • The Catholic University of Korea St. Mary s Hospital ( Site 3104)

    Seoul, 06591, South Korea

  • The Cleveland Clinic Foundation Taussig Cancer Center ( Site 1065)

    Cleveland, Ohio, 44195, United States

  • Tufts Medical Center - PPDS ( Site 1014)

    Boston, Massachusetts, 02111-1526, United States

  • UCLA Medical Center ( Site 1068)

    Los Angeles, California, 90095, United States

  • UZ Gasthuisberg ( Site 1401)

    Leuven, Vlaams-Brabant, 3000, Belgium

  • Uniklinik Köln ( Site 1511)

    Cologne, North Rhine-Westphalia, 50937, Germany

  • Universitaetsklinik Regensburg ( Site 1503)

    Regensburg, Bavaria, 93053, Germany

  • Universitaetsklinik und Poliklinik Halle/Saale ( Site 1502)

    Halle, Saxony-Anhalt, 06120, Germany

  • Universitaetsklinikum Carl Gustav Carus ( Site 1501)

    Dresden, Saxony, 01307, Germany

  • Universitaetsklinikum Giessen und Marburg GmbH ( Site 1512)

    Bad Oeynhausen, North Rhine-Westphalia, 35392, Germany

  • Universitaetsklinikum Heidelberg ( Site 1509)

    Heidelberg, Baden-Wurttemberg, 69120, Germany

  • Universitatsklinikum Leipzig ( Site 1508)

    Leipzig, Saxony, 04103, Germany

  • Universitatsklinikum des Saarlandes ( Site 1513)

    Homburg, Saarland, 66421, Germany

  • University Clinical Center Nis ( Site 2904)

    Niš, Nisavski Okrug, 18000, Serbia

  • University Hospital Centre Split city ( Site 3901)

    Split, Split-Dalmatia County, 21000, Croatia

  • University of Alberta Hospital ( Site 2101)

    Edmonton, Alberta, T6G 2B7, Canada

  • University of Arizona ( Site 1006)

    Tucson, Arizona, 85724, United States

  • University of California Davis Medical Center ( Site 1064)

    Sherman Oaks, California, 95817, United States

  • University of California Irvine ( Site 1086)

    Orange, California, 92868, United States

  • University of California San Diego ( Site 1002)

    La Jolla, California, 92037, United States

  • University of Cincinnati ( Site 1035)

    Cincinnati, Ohio, 45219, United States

  • University of Colorado Hospital ( Site 1013)

    Aurora, Colorado, 80045, United States

  • University of Iowa Hospital and Clinics ( Site 1050)

    Iowa City, Iowa, 52242, United States

  • University of Kansas Medical Center ( Site 1020)

    Kansas City, Missouri, 66160, United States

  • University of Michigan ( Site 1011)

    Ann Arbor, Michigan, 48109, United States

  • University of New Mexico, Health Sciences Center ( Site 1048)

    Albuquerque, New Mexico, 87131, United States

  • University of North Carolina at Chapel Hill ( Site 1042)

    Chapel Hill, North Carolina, 27514, United States

  • University of Texas Southwestern Medical Center ( Site 1038)

    Dallas, Texas, 78701, United States

  • University of Utah ( Site 1049)

    Salt Lake City, Utah, 84132-0001, United States

  • UniversitätsSpital Zürich ( Site 3301)

    Zurich, 8091, Switzerland

  • VU Medisch Centrum ( Site 2601)

    Amsterdam, North Holland, 1081 HV, Netherlands

  • Vanderbilt University Medical Center ( Site 1027)

    Nashville, Tennessee, 37232, United States

  • Vseobecna fakultni nemocnice v Praze ( Site 2201)

    Prague, 128 08, Czechia

  • Waikato District Health Board ( Site 2702)

    Hamilton, Waikato Region, 3204, New Zealand

  • Washington University School of Medicine ( Site 1022)

    St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.